ReviewInflammopharmacology2026
Ultra-deformable transethosomal vesicle for enhancing transdermal delivery of NSAIDs: a comprehensive review.
Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical and transdermal drug delivery methods provide an enticing option to conventional oral administration of non-steroidal anti-inflammatory medications (NSAIDs) by diminishing gastrointestinal complications and bypassing hepatic first-pass metabolism. However, the therapeutic performance of topical NSAID formulations is commonly restricted by the barrier characteristics of the stratum corneum, causing poor drug diffusion and suboptimal concentrations at the desired region. Transethosomes, a cutting-edge generation of ultra-deformable lipid vesicles formed from phospholipids, ethanol, and edge activators, have shown as viable nanocarriers for mitigating these limits. The improved pliability, compact vesicle size, and remarkable skin-penetration capacity support the effective transfer of encapsulated medicines through the skin, culminating in better bioavailability and therapeutic benefits. This review thoroughly outlines the composition, physicochemical characteristics, mechanisms of skin permeation, methods of preparation, and characterization techniques of transethosomal vesicles. Special attention is directed towards their use in the transdermal delivery of NSAIDs, underscoring results from preclinical studies that reveal improved skin permeation, greater drug retention, prolonged drug release, and enhanced anti-inflammatory effectiveness. Current challenges, such as formulation stability, large-scale manufacturing, and clinical translation, are thoroughly examined. Transethosomal vesicles serve as a versatile and promising platform for improving transdermal delivery of NSAIDs, potentially playing a significant role in the advancement of safer and more effective therapeutic strategies for inflammatory disorders.
Indexed as
Identifiers
42572049What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.